Crinetics Pharmaceuticals, Inc. (CRNX)
Largest Insider Buys in Sector
CRNX Stock Price History Chart
CRNX Stock Performance
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing …
Insider Activity of Crinetics Pharmaceuticals, Inc.
Over the last 12 months, insiders at Crinetics Pharmaceuticals, Inc. have bought $0 and sold $26.01M worth of Crinetics Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Crinetics Pharmaceuticals, Inc. have bought $11.86M and sold $10.93M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $110,300 was made by Vivaldi Coelho Rogerio (director) on 2023‑06‑08.
List of Insider Buy and Sell Transactions, Crinetics Pharmaceuticals, Inc.
| 2024-10-03 | Sale | Chief Med and Dev Officer | 14,375 0.0194% | $54.63 | $785,306 | +6.05% | ||
| 2024-09-26 | Sale | CFO | 25,000 0.0317% | $51.11 | $1.28M | 0.00% | ||
| 2024-09-10 | Sale | Chief Scientific Officer | 1,035 0.0013% | $51.50 | $53,303 | +5.45% | ||
| 2024-08-26 | Sale | Chief Scientific Officer | 3,000 0.0038% | $53.19 | $159,570 | -0.08% | ||
| 2024-08-12 | Sale | Chief Scientific Officer | 3,000 0.0036% | $47.68 | $143,040 | +7.18% | ||
| 2024-07-25 | Sale | CFO | 19,056 0.0244% | $53.88 | $1.03M | -0.59% | ||
| 2024-07-25 | Sale | Chief Scientific Officer | 3,000 0.0038% | $53.43 | $160,290 | -0.59% | ||
| 2024-07-15 | Sale | CFO | 25,000 0.0413% | $55.00 | $1.38M | 0.00% | ||
| 2024-07-15 | Sale | Chief Operating Officer | 27,000 0.0446% | $55.00 | $1.49M | 0.00% | ||
| 2024-07-10 | Sale | Chief Scientific Officer | 3,000 0.0044% | $48.55 | $145,650 | 0.00% | ||
| 2024-07-05 | Sale | Chief Commercial Officer | 15,000 0.0199% | $44.08 | $661,200 | 0.00% | ||
| 2024-07-03 | Sale | Chief Med and Dev Officer | 14,375 0.0194% | $44.87 | $645,006 | 0.00% | ||
| 2024-06-28 | Sale | CFO | 32,129 0.0421% | $43.61 | $1.4M | 0.00% | ||
| 2024-06-26 | Sale | Chief Operating Officer | 956 0.0013% | $44.38 | $42,427 | +25.81% | ||
| 2024-06-25 | Sale | Chief Scientific Officer | 3,000 0.0038% | $45.37 | $136,110 | +18.25% | ||
| 2024-06-24 | Sale | Chief Med and Dev Officer | 9,500 0.0121% | $45.73 | $434,435 | +16.13% | ||
| 2024-06-21 | Sale | Chief Commercial Officer | 15,000 0.019% | $44.66 | $669,900 | +16.26% | ||
| 2024-06-10 | Sale | Chief Scientific Officer | 3,000 0.0037% | $43.86 | $131,580 | +17.24% | ||
| 2024-05-28 | Sale | Chief Scientific Officer | 3,000 0.0039% | $47.49 | $142,470 | +11.23% | ||
| 2024-05-10 | Sale | Chief Scientific Officer | 3,000 0.0039% | $49.43 | $148,290 | +7.83% |
Insider Historical Profitability
| Struthers Richard Scott | President & CEO | 257485 0.286% | $59.09 | 2 | 13 | +35.75% |
| EDELMAN JOSEPH | 5321032 5.9099% | $59.09 | 1 | 0 | <0.0001% | |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5163517 5.735% | $59.09 | 5 | 0 | +3.73% |
| Vivo Capital VIII, LLC | 10 percent owner | 298625 0.3317% | $59.09 | 1 | 13 | +10.46% |
| 5AM Ventures IV, L.P. | 94489 0.1049% | $59.09 | 1 | 3 | +10.46% |
Institutional Investor Ownership
| BlackRock | $254.46M | 6.89 | 5.44M | +1.7% | +$4.26M | 0.01 | |
| Driehaus Capital Management LLC | $244.64M | 6.63 | 5.23M | +3.7% | +$8.72M | 2.43 | |
| Point72 Asset Management | $231.69M | 6.28 | 4.95M | +44.85% | +$71.74M | 0.34 | |
| Fidelity Investments | $208.94M | 5.66 | 4.46M | +10.38% | +$19.65M | 0.01 | |
| Ecor1 Capital Llc | $194.51M | 5.27 | 4.16M | +106.48% | +$100.31M | 1.37 |